-
Health Care Select Sector SPDR (XLV $138.17)
- $138.17 P/E (TTM): 83.67X Cap: $33.42B
- View XLV Profile
- View Questions on XLV
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}
{tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}
{tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
{data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
-
BMO S&P 500 Index ETF (ZSP $97.94)
- $97.94 P/E (TTM): 80.87X Cap: $19.53B
- View ZSP Profile
- View Questions on ZSP
-
iShares S&P/TSX Canadian Dividend Aristocrats Index ETF (CDZ $39.20)
- $39.20 P/E (TTM): 5.55X Cap: $1.01B
- View CDZ Profile
- View Questions on CDZ
-
Vanguard U.S. Dividend Appreciation Index ETF (VGG $99.51)
- $99.51 Cap: $2.13B
- View VGG Profile
- View Questions on VGG
-
Financial Select Sector SPDR (XLF $53.57)
- $53.57 P/E (TTM): 43.38X Cap: $53.42B
- View XLF Profile
- View Questions on XLF
-
Consumer Staples Select Sector SPDR (XLP $82.47)
- $82.47 P/E (TTM): 43.8X Cap: $16.63B
- View XLP Profile
- View Questions on XLP
-
Health Care Select Sector SPDR (XLV $138.17)
- $138.17 P/E (TTM): 83.67X Cap: $33.42B
- View XLV Profile
- View Questions on XLV
-
Technology Select Sector SPDR ETF (XLK $262.42)
- $262.42 P/E (TTM): 94.08X Cap: $83.80B
- View XLK Profile
- View Questions on XLK
-
Industrial Select Sector SPDR (XLI $153.14)
- $153.14 P/E (TTM): 87.2X Cap: $23.66B
- View XLI Profile
- View Questions on XLI
-
Communication Services Select Sector SPDR Fund (XLC $111.31)
- $111.31 P/E (TTM): 32.18X Cap: $25.42B
- View XLC Profile
- View Questions on XLC
-
BMO Nasdaq 100 Equity Index ETF (ZNQ $105.16)
- $105.16 P/E (TTM): 102.2X Cap: $1.14B
- View ZNQ Profile
- View Questions on ZNQ
Q: I am coming into a $50,000 gift from aging parents, and would like to invest for my 10 month old son’s education. I want long term growth until he needs the money (probably 18 years or so). Would you recommend 100% ZSP or some other ETF? Also, should I buy in one shot as soon as I have the money ?
-
Health Care Select Sector SPDR (XLV $138.17)
- $138.17 P/E (TTM): 83.67X Cap: $33.42B
- View XLV Profile
- View Questions on XLV
-
iShares U.S. Medical Devices ETF (IHI $62.87)
- $62.87 P/E (TTM): 164.7X Cap: $4.41B
- View IHI Profile
- View Questions on IHI
Q: Health care as a sector has me puzzled. I was adding to my positions in XLV and IHI during 2023-2024. I was prompted to keep investing thinking demographics would favor growth; that elective medical procedures postponed would come roaring back in the years following Covid. Mostly good companies were held in the above ETFs, and I was comfortable investing also because of familiarity with products and services. Markets have proven me wrong. My cost base is markedly higher than valuations today. XLV is down ~5.25% over the past 12 months (year-to-date return is flat —down -0.05%).IHI, although slightly up ~4.28% YTD, has still not recovered from a 20% drop in 2022. (Losses I show are much greater and are not useable for tax).
Current officials in the US admin have no clue on how to go about drug price reforms. Worse: they don’t know that they have no clue. Reforms are necessary; and PBMs are rightly under scrutiny for opaque pricing practices. I say this notwithstanding that UNH has produced the largest dollar loss I have had in several years.
The science and med professionals who DO know how to implement sensible and substantial changes are fired and replaced by sycophantic, subservient ignorant types. Is it therefore prudent now to sell one or both of XLV and IHI and redeploy cash in other areas? OR, would one be giving up at possibly the exact wrong time? Is now finally the time that patience with XLV and IHI has a greater chance of paying off?
Current officials in the US admin have no clue on how to go about drug price reforms. Worse: they don’t know that they have no clue. Reforms are necessary; and PBMs are rightly under scrutiny for opaque pricing practices. I say this notwithstanding that UNH has produced the largest dollar loss I have had in several years.
The science and med professionals who DO know how to implement sensible and substantial changes are fired and replaced by sycophantic, subservient ignorant types. Is it therefore prudent now to sell one or both of XLV and IHI and redeploy cash in other areas? OR, would one be giving up at possibly the exact wrong time? Is now finally the time that patience with XLV and IHI has a greater chance of paying off?
-
Gilead Sciences Inc. (GILD $114.77)
- $114.77 P/E (TTM): 24.4X Cap: $142.40B
- View GILD Profile
- View Questions on GILD
-
Intuitive Surgical Inc. (ISRG $476.16)
- $476.16 P/E (TTM): 65.44X Cap: $170.69B
- View ISRG Profile
- View Questions on ISRG
-
AbbVie Inc. (ABBV $210.60)
- $210.60 P/E (TTM): 89.53X Cap: $372.03B
- View ABBV Profile
- View Questions on ABBV
-
Johnson & Johnson (JNJ $179.29)
- $179.29 P/E (TTM): 19.14X Cap: $431.79B
- View JNJ Profile
- View Questions on JNJ
-
Eli Lilly and Company (LLY $711.68)
- $711.68 P/E (TTM): 57.76X Cap: $673.57B
- View LLY Profile
- View Questions on LLY
-
Medtronic plc. (MDT $92.71)
- $92.71 P/E (TTM): 25.24X Cap: $118.78B
- View MDT Profile
- View Questions on MDT
-
Stryker Corporation (SYK $394.22)
- $394.22 P/E (TTM): 50.97X Cap: $150.71B
- View SYK Profile
- View Questions on SYK
-
Thermo Fisher Scientific Inc (TMO $499.99)
- $499.99 P/E (TTM): 27.98X Cap: $188.80B
- View TMO Profile
- View Questions on TMO
-
Health Care Select Sector SPDR (XLV $138.17)
- $138.17 P/E (TTM): 83.67X Cap: $33.42B
- View XLV Profile
- View Questions on XLV
-
iShares U.S. Medical Devices ETF (IHI $62.87)
- $62.87 P/E (TTM): 164.7X Cap: $4.41B
- View IHI Profile
- View Questions on IHI
-
Sabra Health Care REIT Inc. (SBRA $19.55)
- $19.55 P/E (TTM): 32.7X Cap: $4.68B
- View SBRA Profile
- View Questions on SBRA
-
Healthcare Realty Trust Incorporated (HR $16.97)
- $16.97 Cap: $5.96B
- View HR Profile
- View Questions on HR
-
iShares U.S. Pharmaceuticals ETF (IHE $70.99)
- $70.99 P/E (TTM): 63.66X Cap: $582M
- View IHE Profile
- View Questions on IHE
-
Catalyst Pharmaceuticals Inc. (CPRX $21.08)
- $21.08 P/E (TTM): 12.46X Cap: $2.58B
- View CPRX Profile
- View Questions on CPRX
Q: There was an article in the Globe and Mail today by David Rosenberg about the aging population and he suggested health care related investments such as health care REITS, pharma, devices, and services. What do you think of this idea and can you give me a few recommendations in canada and the US for each of the 4 categories (health reits, pharma, devices, sefrvices)? A mix of ETFS and individual stocks would be great.
Insiders
Share Information
SEC Filings
News and Media